ACNU Technology Platform to Pioneer New Nonprescription Drug Approvals and Empower Self-Care.
Idea Evolver
Software Development
Philadelphia, PA 22,585 followers
Accelerating access.
About us
Uniquely positioning pharmaceuticals in the marketplace through FDA compliant technology and precision digital marketing. Recognized as a leader in ACNU technology and designation, and with an extensive background in pharmaceutical promotion, we specialize in the innovation, regulatory rigor and commercial strategy required to bring these solutions to launch and empower self-care. - ACNU Technology Platform Provider. - Digital Rx to Nonprescription Switch Leader. - Digital Clinical Trial Recruiter and Lifecycle Manager. - Commercial SEO/SEA Partner.
- Website
-
https://ideaevolver.com/
External link for Idea Evolver
- Industry
- Software Development
- Company size
- 11-50 employees
- Headquarters
- Philadelphia, PA
- Type
- Privately Held
- Founded
- 2011
- Specialties
- acnu, rx to otc switch, and pharmaceutical marketing
Locations
-
Primary
Get directions
1315 Walnut Street
Suite 932
Philadelphia, PA 19107, US
Employees at Idea Evolver
Updates
-
“According to Towers, some 90% of the data that’s currently “active” in the life sciences and pharmaceuticals industry was created in just the last two years. As the industry trends toward digitizing, the volume of data gathered from customers is “going to explode.”
Digitalization could be the answer to better health care for patients. But first, they need to trust it
fortune.com
-
"Given this substantial Rx ED market, we believe that the prospects of expanded nonprescription access of prescription-grade ED therapy has the potential to significantly multiply this market's growth. With several recently publicized positive OTC switch events, and the potential for applying the principals of AI to ensure that those who are appropriate to receive it do, we have boldly identified this mission of developing STENDRA as the potentially first prescription-grade pharmaceutical available without a prescription, as our primary objective as a company. The company believes that its technology platform designed for this program may also apply to future asset candidates, enabling an expansion to the company's future portfolio and overall opportunity."
Petros Pharmaceuticals Announces Capital Raise of $15 Million
finance.yahoo.com